Sökning: id:"swepub:oai:DiVA.org:liu-150251" >
Canagliflozin and H...
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
-
- Rådholm, Karin, 1976- (författare)
- Linköpings universitet,Avdelningen för samhällsmedicin,Medicinska fakulteten,Region Östergötland, Vårdcentralen Ödeshög,Univ New South Wales, Australia
-
- Figtree, Gemma (författare)
- Royal North Shore Hosp, Sydney, NSW, Australia
-
- Perkovic, Vlado (författare)
- Univ New South Wales, Australia; Univ Sydney, Australia
-
visa fler...
-
- Solomon, Scott D. (författare)
- Harvard Med Sch, MA USA; Brigham and Womens Hosp, MA 02115 USA
-
- Mahaffey, Kenneth W. (författare)
- Stanford Univ, CA 94305 USA
-
- de Zeeuw, Dick (författare)
- Univ Groningen, Netherlands
-
- Fulcher, Greg (författare)
- Royal North Shore Hosp, Sydney, NSW, Australia
-
- Barrett, Terrance D. (författare)
- Janssen Res and Dev LLC, NJ USA
-
- Shaw, Wayne (författare)
- Janssen Res and Dev LLC, NJ USA
-
- Desai, Mehul (författare)
- Janssen Res and Dev LLC, NJ USA
-
- Matthews, David R. (författare)
- Univ Oxford, England; Univ Oxford, England
-
- Neal, Bruce (författare)
- Univ New South Wales, Australia; Univ New South Wales, Australia; Univ Sydney, Australia; Imperial Coll London, England
-
visa färre...
-
(creator_code:org_t)
- LIPPINCOTT WILLIAMS & WILKINS, 2018
- 2018
- Engelska.
-
Ingår i: Circulation. - : LIPPINCOTT WILLIAMS & WILKINS. - 0009-7322 .- 1524-4539. ; 138:5, s. 458-468
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://liu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure (HF) and cardiovascular death overall, in those with and without a baseline history of HF, and in other participant subgroups. Methods: The CANVAS Program (Canagliflozin Cardiovascular Assessment Study) enrolled 10142 participants with type 2 diabetes mellitus and high cardiovascular risk. Participants were randomly assigned to canagliflozin or placebo and followed for a mean of 188 weeks. The primary end point for these analyses was adjudicated cardiovascular death or hospitalized HF. Results: Participants with a history of HF at baseline (14.4%) were more frequently women, white, and hypertensive and had a history of prior cardiovascular disease (all Pamp;lt;0.001). Greater proportions of these patients were using therapies such as blockers of the renin angiotensin aldosterone system, diuretics, and -blockers at baseline (all Pamp;lt;0.001). Overall, cardiovascular death or hospitalized HF was reduced in those treated with canagliflozin compared with placebo (16.3 versus 20.8 per 1000 patient-years; hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67-0.91), as was fatal or hospitalized HF (HR, 0.70; 95% CI, 0.55-0.89) and hospitalized HF alone (HR, 0.67; 95% CI, 0.52-0.87). The benefit on cardiovascular death or hospitalized HF may be greater in patients with a prior history of HF (HR, 0.61; 95% CI, 0.46-0.80) compared with those without HF at baseline (HR, 0.87; 95% CI, 0.72-1.06; P interaction =0.021). The effects of canagliflozin compared with placebo on other cardiovascular outcomes and key safety outcomes were similar in participants with and without HF at baseline (all interaction P values amp;gt;0.130), except for a possibly reduced absolute rate of events attributable to osmotic diuresis among those with a prior history of HF (P=0.03). Conclusions: In patients with type 2 diabetes mellitus and an elevated risk of cardiovascular disease, canagliflozin reduced the risk of cardiovascular death or hospitalized HF across a broad range of different patient subgroups. Benefits may be greater in those with a history of HF at baseline. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01032629 and NCT01989754.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- canagliflozin; heart failure; randomized trial; SGLT2 inhibitor; type 2 diabetes mellitus
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Rådholm, Karin, ...
-
Figtree, Gemma
-
Perkovic, Vlado
-
Solomon, Scott D ...
-
Mahaffey, Kennet ...
-
de Zeeuw, Dick
-
visa fler...
-
Fulcher, Greg
-
Barrett, Terranc ...
-
Shaw, Wayne
-
Desai, Mehul
-
Matthews, David ...
-
Neal, Bruce
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Circulation
- Av lärosätet
-
Linköpings universitet